Atossa Therapeutics, Inc. (ATOS) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Atossa Therapeutics reported revenue of $0. Net income was -$34.8M, or -$4.04 per diluted share. Operating activities generated -$29.8M of cash, leaving -$29.8M of free cash flow. At fiscal year end, Atossa Therapeutics held $47.6M in total assets against $8.3M in total liabilities, including $41.3M of cash and equivalents.
Open the full interactive Atossa Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Atossa Therapeutics Key Stats
| Share Price | $2.56 |
|---|---|
| Market Cap | $22.8M |
| 52-Week Range | $1.75 – $15.75 |
| Shares Outstanding | 8.9 million (basic, 2026 Q2) |
Atossa Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$14.6M | -$20.5M | -$27.7M | -$31.4M | -$27.6M | -$37.1M |
| Pre-Tax Income | -$17.8M | -$20.6M | -$27.0M | -$30.1M | -$25.5M | -$34.8M |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$17.8M | -$20.6M | -$27.0M | -$30.1M | -$25.5M | -$34.8M |
| Diluted EPS | -$29.55 | -$2.70 | — | -$3.60 | -$3.00 | -$4.04 |
Atossa Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$8.7M | -$10.9M | -$9.6M | -$8.5M |
| Diluted EPS | -$1.05 | -$1.27 | -$1.11 | -$0.95 |
Atossa Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $39.6M | $136.4M | $110.9M | $88.5M | $71.1M | $41.3M |
| Current Assets | $42.8M | $141.2M | $118.2M | $92.2M | $74.5M | $45.6M |
| Total Assets | $42.8M | $141.3M | $123.5M | $96.3M | $76.4M | $47.6M |
| Current Liabilities | $15.7M | $3.1M | $5.6M | $5.2M | $5.0M | $8.3M |
| Total Liabilities | $15.7M | $3.1M | $5.6M | $5.2M | $5.0M | $8.3M |
| Shareholders' Equity | $27.2M | $138.1M | $118.0M | $91.0M | $71.5M | $39.4M |
Atossa Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$11.6M | -$16.5M | -$20.8M | -$20.9M | -$21.0M | -$29.8M |
| Cash From Investing | -$9,367 | -$9,000 | -$4.7M | -$14,000 | -$19,000 | -$23,000 |
| Cash From Financing | $38.6M | $113.3M | $0 | -$1.5M | $3.7M | $0 |
| Free Cash Flow | -$11.6M | -$16.5M | -$20.8M | -$20.9M | -$21.0M | -$29.8M |
Figures from Atossa Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Atossa Therapeutics financials page for every line item.
Atossa Therapeutics Company Profile
| Ticker | ATOS |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Seattle, Washington |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001488039 |
Frequently Asked Questions
What was Atossa Therapeutics' revenue in fiscal 2025?
Atossa Therapeutics (ATOS) reported revenue of $0 for fiscal 2025.
What is Atossa Therapeutics' annual revenue history?
Atossa Therapeutics' annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Atossa Therapeutics' net income in fiscal 2025?
Atossa Therapeutics reported net income of -$34.8M for fiscal 2025.
What was Atossa Therapeutics' earnings per share (EPS) in fiscal 2025?
Atossa Therapeutics' diluted EPS was -$4.04 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Atossa Therapeutics generate in fiscal 2025?
Atossa Therapeutics generated -$29.8M of free cash flow in fiscal 2025.
What was Atossa Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Atossa Therapeutics reported revenue of $0.
How many shares of Atossa Therapeutics are outstanding?
Atossa Therapeutics reported a weighted average of 8.9 million basic shares outstanding in 2026 Q2.
What is Atossa Therapeutics' market cap?
Based on its latest closing price, Atossa Therapeutics (ATOS) has a market capitalization of about $22.8M.
When does Atossa Therapeutics' fiscal year end?
Atossa Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Atossa Therapeutics headquartered?
Atossa Therapeutics lists its business address in Seattle, Washington in its SEC filings.